

Kenneth H Eckels

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7428259/publications.pdf>

Version: 2024-02-01

19
papers

1,245
citations

623734

14
h-index

794594

19
g-index

19
all docs

19
docs citations

19
times ranked

1473
citing authors

#	ARTICLE	IF	CITATIONS
1	Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2090-2105.	3.3	5
2	Dengue Virus Exposures among Deployed U.S. Military Personnel. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 96, 16-0663.	1.4	3
3	Phase I Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United States. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 96, 1325-1337.	1.4	50
4	Long-Term Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine and Evaluation of a Booster Dose Administered to Healthy Thai Children. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 94, 1348-1358.	1.4	5
5	Rapid development of a DNA vaccine for Zika virus. <i>Science</i> , 2016, 354, 237-240.	12.6	348
6	A Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto Rico. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 93, 441-453.	1.4	32
7	Safety and Immunogenicity of a Rederived, Live-Attenuated Dengue Virus Vaccine in Healthy Adults Living in Thailand: A Randomized Trial. <i>American Journal of Tropical Medicine and Hygiene</i> , 2014, 91, 119-128.	1.4	38
8	A Phase II, Randomized, Safety and Immunogenicity Study of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Adults. <i>American Journal of Tropical Medicine and Hygiene</i> , 2013, 88, 73-88.	1.4	86
9	Interference and Facilitation Between Dengue Serotypes in a Tetravalent Live Dengue Virus Vaccine Candidate. <i>Journal of Infectious Diseases</i> , 2011, 204, 442-450.	4.0	40
10	Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine in Flavivirus-Naive Infants. <i>American Journal of Tropical Medicine and Hygiene</i> , 2011, 85, 341-351.	1.4	67
11	Safety and Immunogenicity of a Tetravalent Live-attenuated Dengue Vaccine in Flavivirus Naive Children. <i>American Journal of Tropical Medicine and Hygiene</i> , 2008, 78, 426-433.	1.4	84
12	Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. <i>American Journal of Tropical Medicine and Hygiene</i> , 2008, 78, 426-33.	1.4	39
13	Formalin-inactivated Whole Virus and Recombinant Subunit Flavivirus Vaccines. <i>Advances in Virus Research</i> , 2003, 61, 395-418.	2.1	39
14	MODIFICATION OF DENGUE VIRUS STRAINS BY PASSAGE IN PRIMARY DOG KIDNEY CELLS: PREPARATION OF CANDIDATE VACCINES AND IMMUNIZATION OF MONKEYS. <i>American Journal of Tropical Medicine and Hygiene</i> , 2003, 69, 12-16.	1.4	52
15	PHASE I TRIAL OF 16 FORMULATIONS OF A TETRAVALENT LIVE-ATTENUATED DENGUE VACCINE. <i>American Journal of Tropical Medicine and Hygiene</i> , 2003, 69, 48-60.	1.4	153
16	PROGRESS IN DEVELOPMENT OF A LIVE-ATTENUATED, TETRAVALENT DENGUE VIRUS VACCINE BY THE UNITED STATES ARMY MEDICAL RESEARCH AND MATERIEL COMMAND. <i>American Journal of Tropical Medicine and Hygiene</i> , 2003, 69, 1-4.	1.4	52
17	Preparation of a purified, inactivated Japanese encephalitis (JE) virus vaccine in Vero cells. <i>Biotechnology Letters</i> , 2001, 23, 1565-1573.	2.2	2
18	Nucleotide Sequence of Envelope Protein of Japanese Encephalitis Virus SA ₁₄₋₂ Adapted to Vero Cells. <i>DNA Sequence</i> , 2001, 12, 437-442.	0.7	5

#	ARTICLE	IF	CITATIONS
19	Development of a Purified, Inactivated, Dengue-2 Virus Vaccine Prototype in Vero Cells: Immunogenicity and Protection in Mice and Rhesus Monkeys. <i>Journal of Infectious Diseases</i> , 1996, 174, 1176-1184.	4.0	145